NCT00484536View on ClinicalTrials.gov

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

PHASE2TerminatedINTERVENTIONAL

Enrollment

232

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

July 31, 2010

Conditions

Multiple Sclerosis

Interventions

DRUG

CDP323

250 mg capsules, 500 mg bid (1000 mg/day)

DRUG

placebo

capsules, once daily

DRUG

CDP323

250 mg Capsules, 500 mg, once daily

Trial Locations (71)

Unknown

Cullman

Phoenix

Tucson

Springs

Washington D.C.

Maitland

Atlanta

Northbrook

Fort Wayne

Kansas City

Lenexa

Lexington

Louisville

Farmington Hills

Charlotte

Columbus

Providence

Nashville

Dallas

Kirkland

Charleston

Milwaukee

Diepenbeek

Ghent

Melsbroek

Overpelt

Sijsele

Sint-Truiden

London

Ottawa

Gatineau

Greenfield Park

Sherbrooke

Oulu

Tampere

Turku

Besançon

Clermont-Ferrand

Lyon

Rennes

Strasbourg

Bayreuth

Berlin

Giessen

Hamburg

Marburg

Rostock

Ulm

Wiesbaden

Budapest

Győr

Nyíregyháza

Pécs

Amsterdam

Breda

Nieuwegein

Nijmegen

Barcelona

Bilbao

Girona

Madrid

Málaga

Oviedo

Santa Cruz de Tenerife

Seville

Gothenburg

Umeå

Hartshill

Newcastle

Nottingham

Sheffield

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Biogen

INDUSTRY

lead

UCB Pharma

INDUSTRY

NCT00484536 - Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323 | Biotech Hunter | Biotech Hunter